T1	condition 14 23	bone loss
T2	intervention 29 40	risedronate
T3	No-of-participants 904 907	109
T4	eligibility 908 1040	postmenopausal women with low bone mass on an AI (anastrozole, letrozole, or exemestane) for hormone-receptor-positive breast cancer
T5	control 1107 1114	placebo
T6	outcome-Measure 1192 1195	BMD
T7	outcome-Measure 1197 1300	BTM [carboxy-terminal collagen crosslinks (CTX) and N-terminal propeptide of type 1 procollagen (P1NP)]
T8	outcome-Measure 1306 1312	safety
T9	outcome 1356 1359	BMD
T10	outcome 1542 1552	at the hip
T11	outcome 1574 1593	adjusted difference
T12	outcome 1698 1706	for P1NP
